Skip to main content
SpringerLink
Log in

Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduction in tumor vascularization can easily be detected in responders after 1 or 2 weeks and is correlated with progression-free survival and overall survival in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). DCE-US is supported by the French National Cancer Institute (INCa), which is currently studying the technique in metastatic breast cancer, melanoma, colon cancer, gastrointestinal stromal tumors and renal cell carcinoma, as well as in primary hepatocellular carcinoma, to establish the optimal perfusion parameters and timing for quantitative anticancer efficacy assessments. Currently 490 patients are included in 20 centers and the preliminary results on 400 patients with 1,096 DCE-US demonstrated that AUC could be a robust parameter to predict response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncologist 10:92–103

    Article  CAS  PubMed  Google Scholar 

  2. Schwartz L (2005) Imaging in drug discovery: emerging roles and challenges. In: Plenary session, RSNA Program, Chicago, IL, 27 November-2 December 2005, p 35

  3. Benjamin R (2006) Response of gastrointestinal stromal tumors to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. J Clin Oncol 24(18S):9506

    Google Scholar 

  4. Cosgrove D (2003) Angiogenesis imaging—ultrasound. Br J Radiol 76:S43–S49

    Article  PubMed  Google Scholar 

  5. Lassau N, Koscielny S, Opolon P, De Baere T, Peronneau P, Leclere J, Roche A (2001) Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 36:50–55

    Article  CAS  PubMed  Google Scholar 

  6. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S et al (2002) Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol 13:1029–1035

    Article  CAS  PubMed  Google Scholar 

  7. Greis C (2004) Technology overview: Sonovue (Bracco, Milan). Eur Radiol 14(Suppl 8):P11–P15

    PubMed  Google Scholar 

  8. Lassau N, Lamuraglia M, Vanel D, Le Cesne A, Chami L, Jaziri S et al (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16:1054–1060

    Article  CAS  PubMed  Google Scholar 

  9. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier P et al (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187:1267–1273

    Article  Google Scholar 

  10. Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclère J, Roche A, Lassau N (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472–2479

    Article  CAS  PubMed  Google Scholar 

  11. Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:18011809

    Article  Google Scholar 

  12. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al (2005) Recommendations for the management of GIST patients. Bull Cancer 92:907–918

    PubMed  Google Scholar 

  13. Choi H, Faria S, Benjamin R, Podoloff D, Macapinlac H, Charnsangavej C et al (2002) Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIS) with CT and PET: a quantitative analysis. Proceedings of the RSNA Scientific Program, Chicago, p 583

    Google Scholar 

  14. De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11:6171–6176

    Article  PubMed  Google Scholar 

  15. Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al (2005) Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hepato-Gastro 12:377–389

    Google Scholar 

  16. Lamuraglia M, Le Cesne A, Chami L, Bonvalot S, Terrier P, Tursz T, Roche A, Lassau N (2006) Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncol 24(18S):9539

    Google Scholar 

  17. Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, Bui B, Nguyen B, Bugat R, Chayvialle JA, Rougier P, Bouche O, Bonichon F, Lassau N, Vanel D, Nordlinger B, Stoeckle E, Meeus P, Coindre JM, Scoazec JY, Emile JF, Ranchere D, Blay JY (2006) Recommendations for the management of gastro-intestinal stromal tumors. Ann Pathol 26(3):231–234

    Article  PubMed  Google Scholar 

  18. Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682

    Article  CAS  PubMed  Google Scholar 

  19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  20. Soria JC, Lazar V, Lassau N, Pena C, Massard C, Robert C, Koscielny S, Deutsch E, Zafarana E, Armand JP (2007) Sorafenib (S) and dacarbazine (D) combination in patients with advanced malignant solid tumors: phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). J Clin Oncol 25(18S):3556

    Google Scholar 

  21. Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier B (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast –enhanced ultrasonography. Clin Cancer Res 16(4):1216–1225

    Google Scholar 

  22. Lassau N, Koscielny S, Chebil M, Chami L, Bendjilali R, Roche A, Escudier B, Le Cesne A, Soria J (2009) Functional imaging using DCE-US: which parameters for the early evaluation of antiangiogenetic therapies? 45th Annual meeting of America Society of Clinical Oncology, Nov 2009, Chicago, IL, USA

  23. Lassau N, Lacroix J, Aziza R, Villegrain V, Taieb S, Koscielny S (2009) French Multicentric Prospective Evaluation of Dynamic Contrast-enhanced Ultrasound (DCE-US) for the evaluation of the antiangiogenic treatments. 95th Radiological Society of North America, Nov 2009, Chicago, IL, USA

  24. Pellier J, Chevalier J, Koscielny S, Bonastre J, Benatsou B, Lassau N (2009) Methodological Study to Assess the Evolution of the Quality of Dynamic Contrast-enhanced Ultrasound in a Large National Multicentric Study 95th Radiological Society of North America, Nov 2009, Chicago, IL, USA

Download references

Conflict of Interest statement

No funds were received to support this article.

Author information

Authors and Affiliations

  1. Imaging Department, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94800, Villejuif, France

    Nathalie Lassau, Mohamed Chebil, Linda Chami, Sophie Bidault, Elizabeth Girard & Alain Roche

  2. Imaging Department and IR4M, UMR8081, Ultrasonography Unit, Institut Gustave-Roussy, Villejuif, France

    Nathalie Lassau, Mohamed Chebil, Linda Chami & Alain Roche

Authors
  1. Nathalie Lassau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Chebil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda Chami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sophie Bidault
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elizabeth Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alain Roche
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Lassau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lassau, N., Chebil, M., Chami, L. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Targ Oncol 5, 53–58 (2010). https://doi.org/10.1007/s11523-010-0136-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-010-0136-7

Keywords

Search

Navigation